EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau iD, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B Staber, Tamar Tadmor und 39 weitere

New England Journal of Medicine · 11.05.2023 · 388 (19) · 1739-1754

DOI: 10.1056/nejmoa2213093 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 11.05.2023. Verfasst von Barbara Eichhorst und 50 weiteren Autor:innen. Beteiligte Einrichtung: From the Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Faculty of Medicine and University Hospita…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 315-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: AbbVie, Janssen, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicLeukemia, Lymphocytic, Chronic, B-CellHumansAntineoplastic AgentsAntineoplastic Agents, ImmunologicalBendamustine HydrochlorideCyclophosphamideNeoplasm, ResidualRituximabVidarabineAdeninePiperidinesAntibodies, Monoclonal, HumanizedSulfonamides

Substanzen

Antineoplastic AgentsAntineoplastic Agents, ImmunologicalBendamustine HydrochlorideBridged Bicyclo Compounds, HeterocyclicCyclophosphamideRituximabfludarabineVidarabineibrutinibAdenine

Autor:innen und Institutionen

  • From the Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne (B.E., M.F., C.Z., S.R., F.S…

ORCID-Profile: Moritz Fürstenau, Matthias Ritgen

Förderung

  • AbbVie
  • Janssen
  • Roche

Zitieren

APA

Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Nösslinger, T., …, & GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland (2023). First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(19), 1739-1754. https://doi.org/10.1056/nejmoa2213093

Vancouver

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2023;388(19):1739-1754. doi:10.1056/nejmoa2213093

BibTeX
@article{Eichhorst2023,
  author = {Eichhorst, Barbara and Niemann, Carsten U and Kater, Arnon P and Fürstenau, Moritz and von Tresckow, Julia and Zhang, Can and Robrecht, Sandra and Gregor, Michael and Juliusson, Gunnar and Thornton, Patrick and Staber, Philipp B and Tadmor, Tamar and Lindström, Vesa and da Cunha-Bang, Caspar and Schneider, Christof and Poulsen, Christian B and Illmer, Thomas and Schöttker, Björn and Nösslinger, Thomas and Janssens, Ann and Christiansen, Ilse and Baumann, Michael and Frederiksen, Henrik and van der Klift, Marjolein and Jäger, Ulrich and Leys, Maria B L and Hoogendoorn, Mels and Lotfi, Kourosh and Hebart, Holger and Gaska, Tobias and Koene, Harry and Enggaard, Lisbeth and Goede, Jereon and Regelink, Josien C and Widmer, Anouk and Simon, Florian and De Silva, Nisha and Fink, Anna-Maria and Bahlo, Jasmin and Fischer, Kirsten and Wendtner, Clemens-Martin and Kreuzer, Karl A and Ritgen, Matthias and Brüggemann, Monika and Tausch, Eugen and Levin, Mark-David and van Oers, Marinus and Geisler, Christian and Stilgenbauer, Stephan and Hallek, Michael and GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland},
  title = {First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {19},
  pages = {1739--1754},
  doi = {10.1056/nejmoa2213093}
}
Kostenlos starten →